Does your approach to first line treatment of metastatic colon cancer change for a mucinous adenocarcinoma?

Thanks for the question! I think at this time, molecular features of cancer are more likely to impact treatment choices over histology! For example, we have several biomarker-driven options including MMR-D (KEYNOTE 177, CheckMate 8HW) BRAF (BREAKWATER) and we will likely see similar practice-changin...